Aenova recognized as a winner of CDMO Leadership Awards 2025

Aenova, one of the world's leading contract development and manufacturing organizations, has been selected as a winner in the "Small Molecule Dosage Form - Global" category of the prestigious CDMO Leadership Awards 2025. This underlines the company's global role and recognition in the field of Finished Dosage Forms. The CDMO Leadership Awards recognize the best contract development and manufacturing organizations (CDMOs) across global and regional categories.

Aenova was selected as a participant in the CDMO Leadership Awards 2025, which identifies the best in the industry. More than 210 CDMOs were assessed by global pharmaceutical and biotech customers, based on their work with the providers, on an outsourced project within the past 24 months. Clients submit their ratings of CDMOs based on their recent projects, and the feedback is reviewed to identify the leading CDMOs in each category. Aenova has now been recognized as a winner of the 2025 CDMO Leadership Awards in the Small Molecule Dosage Form - Global category. The company is also a finalist for a Champion Award in the same category.

Contract Development and Manufacturing Organizations (CDMOs) are critical partners to the pharmaceutical industry, providing end-to-end services from development to commercialization. Aenova offers the expertise and infrastructure required to bring small molecule drugs from concept to market. This includes the manufacture of all common types of solids, semi-solids, sterile and non-sterile liquids for the global supply of pharmaceutical products to customers and ultimately patients. Approximately 4,000 employees at 14 production sites contribute to the success of the company. This is reflected in Aenova winning the prestigious 14th annual Outsourced Pharma CDMO Leadership Awards.

"We are very proud to be recognized as a leader in the CDMO industry with this award. It is of particular relevance as it is voted for by our customers, whom we realize have a choice of who they outsource to and vote for. We now look forward to the announcement of the champion among the winners at the awards ceremony in New York on March 19, 2025," said Neil Jones, Chief Commercial Officer of Aenova.

“We are thrilled to introduce our 2025 CDMO Leadership Awards finalists to the Outsourcing community, and honored to offer such an important tool for drug sponsors in selecting their best-fit partner to help bring life-saving therapies to market,” says Outsourced Pharma Chief Editor Louis Garguilo. “The new categories and enhanced scoring methodology that went into this year’s appraisal bring an improved experience for drug sponsors using the resource as well as an ever-so-coveted distinction for the CDMOs. The unveiling of the award champions during our celebration in March will be an exciting new addition to the festivities.”